Innovative Therapeutics K36 Therapeutics is focused on translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics, presenting opportunities for collaborations or licensing deals in the cutting-edge biotech and personalized medicine sectors.

Growing Market Presence With an employee base of up to 50 and revenue between $10M and $25M, K36 Therapeutics demonstrates solid growth potential, making it a promising target for technology or service providers aiming to support biotech innovation and scale-up efforts.

Technology Adoption K36 utilizes advanced tech tools including cloud services and data platforms like Amazon, Metabase, and Workato, indicating a readiness to engage with vendors offering cloud computing, data management, and automation solutions.

Funding & Investment Although specific funding details are not provided, the company's revenue range suggests active investment in research and development, which could be complemented by partnerships or solutions that accelerate drug discovery and epigenetic research.

Industry Trends The biotech sector's increasing focus on epigenetics and oncogenic pathways presents an opportunity to introduce specialized tools, platforms, or consulting services that align with K36 Therapeutics' R&D priorities.